TICKERNERD
Menu
HAEHAEHealthcare · Medical Devices

HAE Stock Forecast: Haemonetics Corp. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$127
+5.94% on the day

The 11 Wall Street analysts covering Haemonetics Corp. hold a median 12-month price target of $128 — +0.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 4 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$5.8B
Ticker Nerd rank
99/ 100
Median analyst target
$128
Analysts covering
11
Revenue$339.4M+5.6% y/y
Operating income$57.5M
Net income$33.0M
Free cash flow$44.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+7.7%
1M
+21.7%
YTD
+59.0%
1Y
+152.9%
From 52W high
0.0%
From 52W low
+152.9%
$50
$127
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HAE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Haemonetics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
99/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Issuance
97
Volatility
93
Accruals
92
Quality
86
Revisions
84
Value
82
Growth
47
Size
21

Momentum (98): The shares have been drifting up relative to others.

Growth (47): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

HAE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HAE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140Jan 26Apr 26Jul 26Oct 26HAEHigh $142Median $128Low $86

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
9 Buy2 Hold0 Sell
Low $86Median $128High $142

The green dot is the last close — the median target sits +0.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Oct 2026Barrington ResearchMaintainsOutperform$118 → $140
9 Oct 2026MizuhoMaintainsOutperform$95 → $140
8 Oct 2026BTIGMaintainsBuy$110 → $130
17 Sept 2026CitigroupUpgradeBuy—
17 Sept 2026CitigroupUpgradeBuy$92 → $123
3 Sept 2026Raymond JamesMaintainsOutperform$105 → $125
3 Sept 2026Raymond JamesMaintainsOutperform—
21 Aug 2026BairdMaintainsOutperform$96 → $119
21 Aug 2026BairdMaintainsOutperform—
19 Aug 2026Barrington ResearchMaintainsOutperform—
19 Aug 2026Barrington ResearchMaintainsOutperform$95 → $118
18 Aug 2026BTIGMaintainsBuy$96 → $110
18 Aug 2026BTIGMaintainsBuy—
7 Aug 2026CitigroupMaintainsNeutral—
7 Aug 2026CitigroupMaintainsNeutral$79 → $92
7 Aug 2026JP MorganMaintainsNeutral—
7 Aug 2026JP MorganMaintainsNeutral$62 → $86
6 Aug 2026BTIGMaintainsBuy$84 → $96
6 Aug 2026BTIGMaintainsBuy—
15 July 2026MizuhoMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

HAE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

HAE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Haemonetics Corp. returned +152.9% against +14.8% for the S&P 500, dividends included.

HAE vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26HAES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HAE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+1.8%
Analysts raising
2
Analysts cutting
0
Fundamentals

Haemonetics Corp. (HAE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
61.6×

Cheaper than 12% of US stocks

Price / sales
4.3×

Cheaper than 29% of US stocks

Price / book
6.9×

Cheaper than 14% of US stocks

EV / EBITDA
18.8×

Cheaper than 17% of US stocks

Growth & margins
Revenue growth (YoY)
5.6%

Higher than 42% of US stocks

Earnings growth (YoY)
−3.0%

Higher than 33% of US stocks

Gross margin
59.8%

Higher than 73% of US stocks

Operating margin
17.9%

Higher than 76% of US stocks

Net margin
7.1%

Higher than 64% of US stocks

Returns & dividend
Return on equity
11.2%

Higher than 66% of US stocks

Return on assets
6.6%

Higher than 83% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Haemonetics Corp. (HAE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Haemonetics Corp. has a market value of $5.8B and an enterprise value of $6.7B.

  • Revenue in the twelve months to 30 June 2026: $1.4B. The latest quarter grew 5.6% year on year.

  • Net income over the same four quarters: $96.3M, a 7.1% net margin.

  • Diluted earnings per share, trailing twelve months: $2.04.

  • Free cash flow in the twelve months to 30 June 2026: $291.2M, after $36.9M of capital spending.

  • Shares outstanding: 45.5M.

  • Trailing P/E: 61.6×; forward P/E: 22.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Haemonetics Corp. employs 3,009 people — $449K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Nov 2026

Data provided by Twelve Data

Peers

HAE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
HAEHaemonetics Corp.$5.8B99
LIVNLivaNova Plc$5.2B96
ITGRInteger Holdings Corp.$4.4B62
IRTCiRhythm Holdings, Inc.$4.4B78
TXG10X Genomics, Inc.$8.8B91
BRKRBruker Corp.$9.7B90
BIOBio-Rad Laboratories, Inc.$10.2B91

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Haemonetics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HAE news & analysis

Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results Available on Investor Relations Website

PRNewsWire · 5 Nov 2026neutral

Haemonetics announced that its fiscal 2027 second-quarter financial results and supplemental presentation are available on its Investor Relations website. The company said it will host a conference call and webcast at 8:00 a.m. to discuss the results and answer questions.

Why it matters — Investors can review HAE’s quarterly results and hear management discuss them during the scheduled call and webcast.

GEHC vs. HAE: Which Stock Is the Better Value Option?

Zacks Investment Research · 29 Oct 2026neutral

Zacks Investment Research frames a comparison of GE HealthCare Technologies and Haemonetics, asking which may be more attractive to value investors. The excerpt provides no analysis or conclusion.

Why it matters — HAE watchers may find the article relevant as it compares Haemonetics with another Medical - Products stock from a value-investing perspective.

Blood Plasma Name Hits Highs On FDA Approval As Earnings Loom

Investors Business Daily · 28 Oct 2026positive

The headline reports that Haemonetics reached highs following an FDA approval, with earnings approaching. The excerpt describes the company’s tools and services for managing blood products, including plasma collection.

Why it matters — The FDA approval and upcoming earnings are developments relevant to investors following Haemonetics.

Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts

Seeking Alpha · 28 Oct 2026neutral

The excerpt describes Ariel Appreciation Fund's Q3 2026 portfolio activity: Charles River Laboratories advanced after strong earnings and higher full-year guidance, NCLH was exited in favor of Royal Caribbean Group, and Middleby spun off Midera Food Processing while announcing a planned exit from an underperforming business and continuing share buybacks.

Why it matters — The excerpt does not mention Haemonetics, so it offers no company-specific information for HAE watchers.

All You Need to Know About Haemonetics (HAE) Rating Upgrade to Buy

Zacks Investment Research · 27 Oct 2026positive

Haemonetics (HAE) was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects.

Why it matters — The upgrade signals a more optimistic assessment of HAE’s earnings prospects in the cited Zacks rating.

FAQ

Frequently asked questions about HAE stock

What is the HAE stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Haemonetics Corp. have a median 12-month price target of $128, with estimates ranging from $86 to $142. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HAE stock a buy right now?

Of the 11 analysts covering Haemonetics Corp., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Haemonetics Corp. 99 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HAE?

As at 4 Nov 2026, Haemonetics Corp. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will HAE stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +0.1% from the last close, and Ticker Nerd's factor model ranks Haemonetics Corp. 99 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HAE stock forecast for 2030?

No analyst covering Haemonetics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HAE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $86 to $142 over the next 12 months.

How has HAE stock performed over the past year?

Haemonetics Corp. returned +152.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Haemonetics Corp. do?

Haemonetics Corporation is a medical technology company that develops products and services for blood and plasma collection, hospital transfusion management, and selected interventional procedures. Its Plasma segment provides automated collection systems, donor management software, and related disposables that support plasma centers and improve operational efficiency.

What is the latest news on HAE?

The most recent item we track (PRNewsWire, 5 Nov 2026): "Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results Available on Investor Relations Website". Haemonetics announced that its fiscal 2027 second-quarter financial results and supplemental presentation are available on its Investor Relations website. The company said it will host a conference call and webcast at 8:00 a.m. to discuss the results and answer questions.

Company

About Haemonetics Corp.

Haemonetics Corporation is a medical technology company that develops products and services for blood and plasma collection, hospital transfusion management, and selected interventional procedures. Its Plasma segment provides automated collection systems, donor management software, and related disposables that support plasma centers and improve operational efficiency. The Blood Center segment offers apheresis and whole blood collection solutions used to collect and process blood components for transfusion. The Hospital segment includes blood management technologies, hemostasis management systems, surgical blood salvage products, vascular closure devices, and sensor-guided tools designed to support clinical decision-making and procedural performance. Headquartered in Boston, Massachusetts, Haemonetics serves healthcare providers and collection centers across global markets.

CEO Mr. Christopher A. Simon · 3,009 employees · United States · https://www.haemonetics.com